HEALTH CARE:
BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS
Nektar Therapeutics develops drug delivery systems meant to improve the performance of a drug molecule or how the drug is delivered (e.g., enabling new dosage form or delivery profile that improves how the therapeutic can treat patients).
| Market Cap | 15.646 Billion | Shares Outstanding | 157.47 Million | Avg Volume | 3.133 Million |
| 1-Yr BETA vs S&P TR | 1.785 | Current Ratio | 5.82 | Quick Ratio | 5.63 |
| Q3 2019 | All Institutions | Hedge Funds 1 |
|---|---|---|
| To trade NKTR now: | |
|
| Filers who had this stock in their top 10: | 1 | 0 (0.0%) |
| 13F Filers holding this stock: | 275 | 26 (2.72%) |
| Aggregate 13F shares on 09/30/2019: | 172.651 Million | 8.057 Million |
| Aggregate 13F shares on 06/30/2019: | 163.516 Million | 8.656 Million |
| Percent change: | 5.59% | -6.91% |
| Funds creating new positions: | 28 | 8 |
| Funds Adding to an existing position: | 125 | 13 |
| Funds closing out their position: | 80 | 14 |
| Funds reducing their position: | 80 | 4 |
| 1 hedge funds as identified by whalewisdom.com through public filings. | ||
View recent insider trading info
Nektar Therapeutics, Inc. Chart by YCharts
Please sign in first
none
179.1 Thousand total shares from 10 transactions
150 Thousand total shares from 5 transactions
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
NORTHCOTT JOHN SVP & CHIEF COMMERCIAL OFFICER |
|
200,000 | 2019-12-02 | 2 |
|
47,042 | 2019-11-20 | 13 | |
|
ROBIN HOWARD W PRESIDENT & CEO |
|
299,629 | 2019-11-18 | 9 |
|
THOMSEN JILLIAN B. SVP & CHIEF ACCOUNTING OFFICER |
|
160,441 | 2019-11-18 | 6 |
|
ZALEVSKY JONATHAN CHIEF R&D OFFICER |
|
291,697 | 2019-11-18 | 3 |
|
22,375 | 2019-09-30 | 3 | |
|
276,973 | 2019-09-27 | 2 | |
|
26,700 | 2019-09-27 | 3 | |
|
151,583 | 2019-09-25 | 2 | |
|
208,250 | 2019-09-25 | 1 | |
|
15,000 | 2019-09-25 | 1 | |
|
DOBERSTEIN STEPHEN K SVP & CHIEF SCIENTIFIC OFFICER |
|
107,668 | 2019-09-05 | 5 |
|
LORIANNE MASUOKA K. CHIEF MEDICAL OFFICER |
|
0 | 2019-08-21 | 0 |
|
NICHOLSON JOHN SVP & CHIEF OPERATING OFFICER |
|
162,759 | 2019-08-16 | 4 |
|
10,000 | 2019-07-01 | 0 | |
|
HORA MANINDER SVP PHARMA DEV & MFG OPS |
|
94,694 | 2019-05-16 | 3 |
|
0 | 2019-03-15 | 0 | |
|
15,510 | 2019-01-02 | 0 | |
|
47,750 | 2018-08-17 | 0 | |
|
0 | 2018-06-22 | 0 | |
|
82,000 | 2017-09-19 | 0 | |
|
414,016 | 2016-06-01 | 0 | |
|
9,887 | 2016-01-25 | 0 | |
|
179,876 | 2014-08-19 | 0 | |
|
MEDVE ROBERT SVP & CHIEF MEDICAL OFFICER |
|
0 | 2014-02-05 | 0 |
|
GHOSH RINKO CHIEF BUSINESS OFFICER |
|
0 | 2013-02-06 | 0 |
|
MOREADITH RANDALL W SVP DRUG DEVELOPMENT |
|
0 | 2009-02-23 | 0 |
|
13,200 | 2009-01-02 | 0 |
| Reporting Owners | Transaction Date | Transaction Code | Shares | Share Price | Acquired or Disposed | Shares Owned Following Transaction | Combined shares owned after filing | Direct/Indirect Ownership | 10b-5 |
|---|---|---|---|---|---|---|---|---|---|
| 2019-12-02 | A | 200,000 | a | 200,000 | 200,000.00 | direct | |||
| 2019-12-02 | A | 200,000 | a | 200,000 | 200,000.00 | direct | |||
| 2019-11-18 | S | 8,863 | $17.97 | d | 219,009 | 219,009.00 | direct | ||
| 2019-11-18 | S | 2,713 | $17.97 | d | 160,441 | 160,441.00 | direct | ||
| 2019-11-18 | S | 13,556 | $17.97 | d | 299,219 | 299,629.00 | direct | ||
| 2019-11-18 | S | 3,960 | $17.97 | d | 291,697 | 291,697.00 | direct | ||
| 2019-11-13 | S | 25,000 | $19.79 | d | 227,872 | 227,872.00 | direct | ||
| 2019-11-13 | M | 25,000 | $7.21 | a | 252,872 | 227,872.00 | direct | ||
| 2019-11-13 | M | 25,000 | d | 0 | 227,872.00 | direct | |||
| 2019-10-17 | M | 33,333 | $7.21 | a | 346,108 | 313,185.00 | direct | ||
| 2019-10-17 | M | 33,333 | d | 0 | 313,185.00 | direct | |||
| 2019-10-17 | S | 33,333 | $17.68 | d | 312,775 | 313,185.00 | direct | ||
| 2019-10-16 | M | 33,334 | d | 33,333 | 313,185.00 | direct | |||
| 2019-10-16 | S | 33,334 | $17.48 | d | 312,775 | 313,185.00 | direct | ||
| 2019-10-16 | M | 33,334 | $7.21 | a | 346,109 | 313,185.00 | direct | ||
| 2019-10-15 | M | 33,333 | $7.21 | a | 346,108 | 313,185.00 | direct | ||
| 2019-10-15 | S | 25,000 | $15.83 | d | 227,872 | 227,872.00 | direct | ||
| 2019-10-15 | S | 24,500 | $17.17 | d | 312,775 | 313,185.00 | direct | ||
| 2019-10-15 | M | 25,000 | $7.21 | a | 252,872 | 227,872.00 | direct | ||
| 2019-10-15 | M | 33,333 | d | 66,667 | 313,185.00 | direct | |||
| 2019-10-15 | S | 8,833 | $16.35 | d | 337,275 | 313,185.00 | direct | ||
| 2019-10-15 | M | 25,000 | d | 25,000 | 227,872.00 | direct |
